Which one is more effective, avatrombopag or eltrombopag?

Avatrombopag and Eltrombopag are thrombopoietin receptor agonists (TPO-RAs) used to treat chronic immune thrombocytopenia (ITP) in adults. Thrombopoietin receptor agonists play a key role in stimulating platelet production, so the choice of which drug to use should be made by the physician based on the patient's specific circumstances and needs. Doctors will consider the patient's condition, drug side effects, drug interactions and other factors to make the best choice.

Some studies suggest that in some patients, avitrombopag may produce a more stable platelet response; in other studies, eltrombopag has shown better efficacy. Avatropopag and eltrombopag had the best platelet responses compared with placebo, with the former showing no significant advantage over the latter, with patients who received avatropopag having a shorter median response time (p=0.012) and higher platelet levels at month two (p=0.041) than patients who received eltrombopag. It follows that both drugs are similarly effective at increasing platelet counts, but which drug is better depends on individual patient differences and response to the drug.

The original drug of avatrombopag has been launched in China and has entered the scope of Class B medical insurance, but it is only reimbursed for eligible patients. The price of a common 20mg*15 tablets may be more than 7,000 yuan per box, while the original drug of avatrombopag marketed overseas is even more expensive. It is understood that there are generic drugs of avatrombopag available overseas, and their pharmaceutical ingredients are basically the same as those of the original drug. For example, the price of a box of 20mg*30 tablets in Laos pharmaceutical production specifications may be around RMB 1,000 (the price may fluctuate due to exchange rates).